Wade May, MD
Cardiovascular Disease · Lafayette, LANPI 1861682239
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $20,598 of the $30,267 with a category attached, or 68.1%. 34 manufacturers reported payments, led by Amgen at 54.8% of the total. Reporting peaked in 2019 at $17,193 and has fallen 96.7% since, to $566 in 2025. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 389 payments — averaging $77.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$17K
- Sanofi-aventis U.S. LLC$5K
- Novartis$1K
- Regeneron Healthcare Solutions, Inc.$1K
- Abiomed$1K
- Boehringer Ingelheim$951
- plus $4K from 28 others
Across 72 payments — averaging $3748.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$115K
- Merck$93K
- CSL Behring$62K
What the payments were for
- Consulting fees$5202%
- Speaking & faculty fees$20,59868%
- Travel & lodging$1,0023%
- Food & beverage$8,07827%
- Education$700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 50 | $16,597 |
| Sanofi-aventis U.S. LLC | 10 | $5,306 |
| Novartis | 82 | $1,322 |
| Regeneron Healthcare Solutions, Inc. | 7 | $1,078 |
| Abiomed | 14 | $1,044 |
| Boehringer Ingelheim | 19 | $951 |
| Johnson & Johnson | 57 | $835 |
| E.r. Squibb & Sons, L.L.C. | 33 | $605 |
| Pfizer | 30 | $461 |
| Merck | 23 | $398 |
| Silk Road Medical, Inc. | 2 | $276 |
| Amarin Pharma, Inc. | 11 | $221 |
| CSL Behring | 1 | $170 |
| AstraZeneca | 11 | $154 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $130 |
| Boston Scientific | 2 | $102 |
| Medtronic(2 entities) | 4 | $101 |
| Kestra Medical Technology Services, Inc. | 1 | $58 |
| Edwards Lifesciences | 1 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Philips North America LLC | 1 | $45 |
| Scpharmaceuticals Inc. | 3 | $43 |
| Bayer | 2 | $42 |
| Arbor Pharmaceuticals, Inc. | 3 | $41 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Cleerly, Inc. | 1 | $25 |
| Cardiovascular Systems Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Abbott | 1 | $21 |
| Novo Nordisk | 1 | $17 |
| Gilead | 1 | $16 |
| Cvrx, Inc. | 1 | $14 |
| Lexicon Pharmaceuticals, Inc. | 1 | $14 |
| Itamar Medical Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$15,700
- PRALUENT$6,064
- Impella$536
- PRADAXA$520
- ENROUTE Transcarotid Neuroprotection System$276
- ENROUTE Transcarotid Stent$276
- LEQVIO$129
- JARDIANCE$122
- CAMZYOS$108
How this compares
$30,267 in reported general payments places this provider in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,372 | $1,163,903 |
| EntrestoSacubitril/Valsartan | 504 | $441,081 |
| XareltoRivaroxaban | 458 | $377,033 |
| Repatha SureclickEvolocumab | 293 | $211,054 |
| JardianceEmpagliflozin | 163 | $134,306 |
| FarxigaDapagliflozin Propanediol | 145 | $111,633 |
| VascepaIcosapent Ethyl | 96 | $42,982 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 176 | $41,528 |
| MultaqDronedarone Hcl | 30 | $40,644 |
| Ezetimibe | 1,887 | $31,431 |
| Metoprolol Succinate | 2,327 | $28,716 |
| Rosuvastatin Calcium | 2,531 | $27,864 |
| Atorvastatin Calcium | 2,333 | $19,220 |
| Ranolazine ErRanolazine | 295 | $18,022 |
| Nebivolol Hcl | 327 | $17,535 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $461 | $1,163,9031,372 claims |
| NovartisEntresto | $1,322 | $441,081504 claims |
| Johnson & JohnsonXarelto | $835 | $377,033458 claims |
| Boehringer IngelheimJardiance, Pradaxa | $951 | $140,452183 claims |
| AstraZenecaFarxiga, Brilinta | $154 | $127,804171 claims |
| Sanofi-aventis U.S. LLCMultaq | $5,306 | $40,64430 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $30 | $13,94231 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $41 | $4,52718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in Lafayette
- Corwin ThomasLafayette$30K
- Brent RochonLafayette$21K
- Syed Fazal Ur RehmanLafayette$12K
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Imran ChaudryMonroe$202K
- Corey FosterLake Charles$158K
- George KaramBaton Rouge$110K
- Harry HawthorneAlexandria$89K
- Mazen IqbalMonroe$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.